GlassScriptPhysician profile
Amber R Warren
NPI 1093034258
$1,689.27
in general payments reported to CMS, 2019-2025
23 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $70.50 · 2021: $36.45 · 2022: $209 · 2023: $335 · 2024: $341 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $507.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $165.48 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $137.76 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Verona Pharma, INC. | $112.39 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $109.14 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $94.01 | 2023-2025 | |
| Organon LLC | $88.93 | 2022-2025 | Nexplanon |
| Abbvie INC. | $85.80 | 2023-2024 | Qulipta |
| Janssen Pharmaceuticals, INC | $57.16 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.29 | 2019-2023 | Xifaxan, Trulance |
| Dexcom, INC. | $35.62 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $31.80 | 2023 | Glassia |
| Medtronic, INC. | $30.37 | 2024 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $26.79 | 2023 | Farxiga |
| Recor Medical INC | $24.10 | 2024 | Paradise Renal Denervation System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.97 | 2025 | Caplyta |
| Roche Diagnostics Corporation | $18.55 | 2019 | |
| Lundbeck LLC | $16.84 | 2025 | Rexulti |
| Exact Sciences Corporation | $15.28 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.91 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.